QUBT Bets on Scale as Rising Costs Weigh on Profitability

Quantum Computing Inc. (QUBT/QCi) logged Q2 2026 revenues of $5.6M (up from $61K) but still posted a gross loss of ~$1.2M, showing growth hasn’t yet translated into profitability. Operating expenses jumped 114% YoY to $21.8M, and the company used ~$180M cash (incl. transaction costs) in H1 2026 for acquisitions, raising integration/execution risk. With QCi shares down 47.9% over the past year and a very high forward P/S of 34.61X vs the industry’s 4.09X, the near-term setup remains valuation- and margin-conversion dependent.

Analysis

QUBT looks like a classic “revenue growth without operating leverage” story: the market is still paying for a future scale option, but the current cost structure implies each incremental dollar of revenue is not yet covering the fixed manufacturing and go-to-market base. In the next 1-3 months, the key driver is not top-line growth but whether management can slow opex growth and demonstrate margin inflection; absent that, estimate cuts and multiple compression can compound quickly from an already elevated sales multiple.

The second-order issue is balance-sheet optionality. Spending a large chunk of cash on acquisitions may buy capability, but it also raises integration risk just as the company needs flawless execution to justify a premium valuation. That dynamic is unfavorable versus peers with clearer recurring usage trajectories, because investors will increasingly discriminate between “lab/contract revenue” and businesses that can show repeatable unit economics; the former should trade at a persistent discount if capital markets tighten.

Contrarian view: the consensus may be underestimating squeeze risk. In a thin, narrative-driven small-cap, any single contract win, backlog conversion, or margin surprise can trigger violent mean reversion, so outright short exposure needs defined risk. Still, over 6-18 months the burden of proof is on QUBT: if gross margin stays negative and opex keeps outrunning revenue, the equity story likely shifts from growth to financing dilution rather than operating leverage.

Key Decisions for Investors

• Short QUBT on strength or via a 1-3 month put spread; target the next leg of estimate downgrades and valuation compression. Use a defined-risk structure because borrow/squeeze risk is high in this tape.
• If already short, tighten risk around any quarter where gross margin turns positive or quarterly revenue clears a meaningful step-up; those are the main falsifiers of the bearish thesis.
• Keep QBTS and RGTI on a relative-value watchlist rather than assuming sector-wide collapse; the better trade may be to short the highest multiple / weakest execution name (QUBT) against the broader quantum basket only if a catalyst confirms differentiation.
• Avoid chasing the stock lower intraday after weak commentary; wait for a rally into liquidity, since this type of name often overreacts both ways and entry price matters more than thesis quality.
• Set an alert for any financing, acquisition integration update, or backlog conversion disclosure over the next 1-2 quarters; those are the catalysts most likely to either validate or break the short.